Scynexis INC 8-K filings

SCYNEXIS, Inc. successfully obtained shareholder approval to increase its authorized common stock to 60 million shares.

SCYNEXIS, Inc. has implemented a one-for-eight reverse stock split effective May 29, 2026, to adjust its capital structure.

SCYNEXIS, Inc. stockholders approved a reverse stock split, with the Board setting a 1-for-8 ratio effective May 29, 2026.

SCYNEXIS, Inc. director Dr. Steven C. Gilman will retire and not stand for reelection at the 2026 Annual Meeting.

SCYNEXIS, Inc. announced the acquisition of global rights for SCY-770, a Phase 2-ready asset for Autosomal Dominant Polycystic Kidney Disease (ADPKD), alongside a $40 million PIPE financing to extend its cash runway.

SCYNEXIS, Inc. announced a $40.0 million private placement of common stock and warrants, extending its operational funding into mid-2029.

SCYNEXIS acquires PXL-770 (now SCY-770), a clinical-stage direct AMPK activator, to target Autosomal Dominant Polycystic Kidney Disease, expanding its rare disease pipeline.

SCYNEXIS and GSK have resolved their disagreement regarding the MARIO study, leading to a $24.3 million payment to SCYNEXIS and continued collaboration on BREXAFEMME.

SCYNEXIS, Inc. announced that all seven director nominees were re-elected, Deloitte & Touche LLP was ratified as the independent auditor, and executive compensation received advisory approval at its 2025 Annual Meeting of Stockholders.

SCYNEXis, Inc. has received a notice from Nasdaq regarding its non-compliance with the minimum bid price rule, initiating a 180-day period to regain compliance.

SCYNEXIS, Inc. has entered into a controlled equity offering agreement with Cantor Fitzgerald to sell up to $50 million of its common stock.

SCYNEXIS, Inc. updated investors on its antifungal development pipeline, including progress on SCY-247 and the MARIO study, and a strengthened balance sheet.

SCYNEXIS, Inc. successfully held its 2024 Annual Meeting of Stockholders, re-electing all proposed directors and approving the ratification of the accounting firm, executive compensation, and the 2024 Equity Incentive Plan.

SCYNEXIS reported a strong financial turnaround in 2023, driven by a significant licensing deal, and is progressing its pipeline with key clinical milestones expected in 2024.